A comparative evaluation of intanasal salmon calcitonin and intravenous zolondrinic acid in the treatment of postmenopausal osteoporosis
Keywords:Osteoporosis, Bone mineral density, Osteopenia, Zolindronic acid, Salmon calcitonin, Postmenopausal
Background: Osteoporosis is a progressive disorder of the bones which is characterized by reduction in bone mass and increased risk of fractures. Various drugs are available for the treatment of osteoporosis and prevention of osteoporotic fractures. Zolindronic acid and salmon calcitonin are the first line of therapy among these. The aim of the study was to compare the effectiveness intanasal salmon calcitonin and intravenous zolondrinic acid the treatment of postmenopausal osteoporosis
Methods: The study was conducted in the Department of Orthopaedics at a tertiary care centre from January 2015 to Jan 2017. One group received treatment with intravenous zolindronic acid 5mg administered as a single dose. Other group received a salmon calcitonin which was administered intranasally 100IU/day. Results were compared.
Results: Total 80 patients were included in the study. Forty patients were allotted to each group. Mean T score of BMD of the patients in the salmon calcitonin group before the start of study was -3.38 and mean T score of the patients in the zolindronic acid group was -3.4. Which improved to -1.9 and -1.49 for the calcitonin group and zolindronic acid treated group respectively.
Conclusions: Once yearly intravenous zolindronic acid is superior to intranasal salmon calcitonin in the treatment of post-menopausal osteoporosis.
Singh H, Goyal M, Singh J. Osteoporosis: current management guidelines. Indian J Clin Practice. 2013;23(12):842-50.
Prasad DV, Pathak RS, Kalakoti P, Syed AMM, Peeyuusha D. The prevalence of osteoporosis and associated factors among health care professionals. Pravara Med Rev. 2010;2(3):24-8.
Frazao P, Naveira M. Treatment of postmenopausal osteoporosis in women: a systematic review. Rev Bras Epidemiol. 2006;9:206-14.
World Health Organization Scientific Group on the Prevention and Management of Osteoporosis. Prevention and management of osteoporosis. Geneva: World Health Organization; 2003. (Technical Report Series, 921).
Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporosis Int. 2013;24(2):393-406.
Jacobs HS. Postmenopausal hormone replacement therapy and breast cancer. Medscape Women's Health. 2000;5(4):E2.
Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132(9):689-96.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.
Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect: Core Evid. 2010;4:13–23.
Shen Y, Li M, Wronski TJ. Calcitonin provides complete protection against cancellous bone loss in the femoral neck of ovariectomized rats. Calcif Tissue Int. 1997;60(5):457–61.
Ogawa K, Hori M, Takao R, Sakurada T. Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab. 2005;23(5):351-8.
Jhaveri S, Upashani T, Bhadauria J, Biswas S, Patel K. Current Clinical Practice Scenario of Osteoporosis Management in India. J Clin Diagn Res. 2015;9(10):RC04–08.
Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, et al. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet. 1987;2(8574):1481-3.
Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008;23(1):6-16.